The EU’s new pharmaceutical strategy recognises that secure, affordable and efficient access to new therapeutics and devices will play a key role in strengthening post-pandemic health systems, improving outcomes for patients, and sustaining the global competitiveness of European firms in various health sectors. Policymakers at the EU and national levels also acknowledge the need for new methods of evidence generation and assessment, such as analysis of big and real-world data, to support the development, authorisation, and use of medicines.
In parallel, scientists are making rapid strides toward the next generation of medicines, in areas such as cell- and gene-based therapies and genomics, while advanced computing, AI, common data spaces and more are pushing back the boundaries of what data science can achieve. As the EU moves forward with its new strategy and landmark revision of its basic pharmaceutical legislation, a vital question is how regulation can anticipate and accommodate these scientific and technological breakthroughs, foster innovation, and remain flexible to future health crises, policy priorities and the concerns of major stakeholders.
Against this backdrop, Science|Business – Europe’s leading media organisation specialised in R&I policy issues – is partnering with EIT Health and others to stage high-level dialogues in various EU capitals to gather national perspectives on this issue (under what we call the Future Proofing Medicines initiative).
The September 28/29 meeting in Berlin is an opportunity for German health sector leaders to present their views on the future of medicines regulation, its potential impact on industry and society, and how the power of medical science, health data and digital innovation can be fully harnessed in the years to come. It will be the second high-level meeting of the Future Proofing Medicines initiative, bridging between an expert roundtable in Copenhagen (June 2022) and a public conference in Stockholm (Q1 2023) during the Swedish Presidency of the European Council.
Economic and financial environment/capitalization and financing of healthcare services
Political, legal, fiscal and regulatory framework conditions
The resilience and innovative capacity of the German healthcare system put to the test
Sustainability in healthcare: Green Healthcare Health DIGITAL – 2025
Head of the New Technologies and Data Use, BMG
Prof. Freimut Schliess
Member of the Supervisory Board, EIT Health
Chief Medical Officer & Managing Director, heartbeat medical
Dr. Christoph Löschmann
Chairman of the Board, Gesundes Kinzigtal GmbH
Dr. Michael Alain Lüttgen
Stakeholder Relations Lead, EIT Health Germany GmbH
Prof. Dr. Dr. Alexander P. F. Ehlers
Specialist in medical law, specialist in general medicine, Ehlers & Partner
Dr. Katharina Ladewig
Managing Director Centre for AI, RKI
The participation fee for the two-day event including conference documents, an invitation to dinner, lunch, drinks during breaks and small snacks is per person: € 1.995,-.
The participation fee for the two-day event incl. conference documents is per person: € 795,-.